The Maharashtra Food and Drug Administration (FDA) has officially withdrawn its controversial order canceling the manufacturing license of domestic pharmaceutical major Cipla, following stern observations from the Bombay High Court regarding procedural overreach.
The legal development, reported by Moneycontrol, centered on regulatory action initiated against Cipla's manufacturing facility over alleged packaging and batch documentation discrepancies. Cipla approached the Bombay High Court challenging the state regulator's summary cancellation, arguing that the enforcement action was disproportionate, procedurally defective, and issued without affording the company an adequate statutory hearing under the Drugs and Cosmetics Act.
During judicial proceedings, a division bench of the High Court cautioned the regulatory authority against arbitrary administrative decisions that disrupt essential pharmaceutical supplies without adhering to principles of natural justice. In response to the court's scrutiny, counsel representing the state FDA informed the bench that the cancellation directive had been formally recalled, rendering the petition disposed of while preserving regulatory oversight under due process.
The legal resolution ensures uninterrupted manufacturing and market distribution of Cipla’s critical pharmaceutical formulations, including vital respiratory therapies and active pharmaceutical ingredients. Industry legal experts noted that the ruling reaffirms judicial limits on administrative agencies, underscoring that statutory compliance enforcement must balance public safety mandates with transparent procedural fairness.
